[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mmrd-endometrial-cancer-of-stage-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mmrd-endometrial-cancer-of-stage-iii":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100649230","phase-2-sintilimab-monotherapy-in-patients-with-stage-i-ii-msi-hdmmr-endometrial-cancer-100649230",false,"NCT07731607","Sintilimab Monotherapy in Patients With Stage I-II MSI-H\u002FdMMR Endometrial Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years.\n2. Histopathologically confirmed endometrial cancer, with pathological types including endometrioid, serous, clear cell, undifferentiated, dedifferentiated, or carcinosarcoma.\n3. Laboratory-confirmed dMMR (mismatch repair deficient) endometrial cancer (loss of MLH1\u002FPMS2\u002FMSH2\u002FMSH6 protein expression by immunohistochemistry) or MSI-H (microsatellite instability-high by PCR or NGS).\n4. Stage I-II according to the FIGO 2023 staging system.\n5. At least one measurable lesion (RECIST 1.1 criteria).\n6. ECOG performance status 0-1, with a life expectancy of ≥12 months.\n7. Strong desire for uterine preservation, conservative treatment, or fertility preservation, or inability to tolerate standard surgery due to comorbidities.\n8. Adequate organ function within 14 days prior to enrollment.\n9. Good follow-up conditions and signed informed consent.\n\nExclusion Criteria:\n\n1. Presence of active autoimmune disease, or long-term requirement for immunosuppressive agents;\n2. Prior treatment with immune checkpoint inhibitors;\n3. Concurrent persistent or active infections, such as hepatitis B, hepatitis C, etc.;\n4. Concurrent severe dysfunction of vital organs including heart, lung, liver and kidney: alanine aminotransferase\u002Faspartate aminotransferase elevated more than 3 times the upper limit of normal (ULN) and unresponsive to liver-protective therapy; serum creatinine ≥1.5 × ULN; abnormal thyroid function; history of heart failure, unstable angina pectoris, severe arrhythmia, myocarditis, interstitial lung disease, non-infectious pneumonitis or active pulmonary infection, etc.;\n5. Other active malignant tumors (except cured basal cell carcinoma of the skin, cervical carcinoma in situ, etc.);\n6. Known hypersensitivity to any component of the study drug;\n7. Pregnant or breastfeeding women;\n8. Any severe or unstable concomitant disease that, in the investigator's judgment, renders the subject ineligible for this study.","FEMALE","18 Years","75 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To investigate the efficacy and safety of immune checkpoint inhibitors as a non-surgical (surgery-avoiding) treatment in patients with stage I-II MSI-H\u002FdMMR endometrial cancer.",[26],"MMRd Endometrial Cancer of Stage I~II",[28,29,30],"endometrial cancer","stage I~II","MMRd","NOT_YET_RECRUITING","2026-07-25",{"date":34,"type":35},"2026-07-28","ACTUAL",{"date":37,"type":20},"2026-07-20",{"date":39,"type":20},"2030-07-20",{"name":41,"class":42},"Wang Jianliu","OTHER"]